title: Glatiramer in the treatment of multiple sclerosis.
abstract: Multiple sclerosis (MS) is a disease of the central nervous system with both an inflammatory and degenerative component. The disease primarily affects young adults and results in significant physical and cognitive disability. Several disease-modifying agents are currently used in the management of multiple sclerosis. Glatiramer acetate (GA, Copaxone, co-polymer 1) is a disease-modifying agent approved for the treatment of relapsing remitting multiple sclerosis. Apart from its unique mode of action, there is evidence pointing toward a possible neuroprotective role. This review will critically discuss GA's potential mechanisms of action, the results of clinical trials, safety profile, and future directions of treatment.
authors: Department of Clinical Neurosciences, Brown Medical School, Rhode Island Hospital, Providence, RI 02905, USA. srizvi@lifespan.org
authors: Syed A
authors: SA
authors: Rizvi
authors: Edward
authors: E
authors: Kim
authors: Jennifer
authors: J
authors: Moodie
mesh_terms: D002986:Clinical Trials as Topic; D000068717:Glatiramer Acetate; D006801:Humans; D007166:Immunosuppressive Agents / Q000008:administration & dosage / Q000009:adverse effects; D018448:Models, Immunological; D009103:Multiple Sclerosis / Q000188:drug therapy* / Q000276:immunology*; D018696:Neuroprotective Agents / Q000008:administration & dosage* / Q000009:adverse effects; D010455:Peptides / Q000008:administration & dosage* / Q000009:adverse effects; D055502:Secondary Prevention
chemical_list: D007166:Immunosuppressive Agents; D018696:Neuroprotective Agents; D010455:Peptides; D000068717:Glatiramer Acetate
references: N Engl J Med. 1987 Aug 13;317(7):408-14
references: 3302705
references: Neurology. 1991 Apr;41(4):533-9
references: 2011253
references: Nature. 1992 Dec 24-31;360(6406):753-5
references: 1281520
references: Neurology. 1995 Jul;45(7):1268-76
references: 7617181
references: Science. 1995 Oct 27;270(5236):593-8
references: 7570017
references: Annu Rev Neurosci. 1996;19:289-317
references: 8833445
references: Nature. 1997 Jan 30;385(6615):391, 393
references: 9009184
references: Nat Med. 1997 Jul;3(7):765-70
references: 9212104
references: N Engl J Med. 1998 Jan 29;338(5):278-85
references: 9445407
references: Neurology. 1998 Apr;50(4):1127-33
references: 9566406
references: AJNR Am J Neuroradiol. 1998 Apr;19(4):675-83
references: 9576653
references: J Neuroimmunol. 1998 Dec 1;92(1-2):113-21
references: 9916886
references: Neurology. 2004 Dec 14;63(11 Suppl 5):S3-11
references: 15596734
references: J Autoimmun. 2005 Mar;24(2):119-24
references: 15829404
references: Neurology. 2005 Apr 26;64(8):1481-2
references: 15851756
references: J Neuroimmunol. 2005 Oct;167(1-2):215-8
references: 16083971
references: N Engl J Med. 2006 Mar 2;354(9):924-33
references: 16510746
references: Mult Scler. 2006 Jun;12(3):309-20
references: 16764344
references: Neurology. 2000 Feb 22;54(4):813-7
references: 10690968
references: J Clin Invest. 2000 Apr;105(7):967-76
references: 10749576
references: Ann Neurol. 2001 Mar;49(3):290-7
references: 11261502
references: J Neuroimmunol. 2001 Apr 2;115(1-2):152-60
references: 11282165
references: Neurology. 2001 Mar 27;56(6):702-8
references: 11288751
references: Mult Scler. 2001 Feb;7(1):33-41
references: 11321192
references: Brain. 2001 Sep;124(Pt 9):1803-12
references: 11522582
references: Neurology. 2001 Aug 28;57(4):731-3
references: 11524494
references: Nat Immunol. 2001 Sep;2(9):785-8
references: 11526386
references: Mult Scler. 2001 Aug;7(4):209-19
references: 11548979
references: Mult Scler. 2001 Dec;7(6):349-53
references: 11795454
references: Clin Neuropharmacol. 2002 Jan-Feb;25(1):11-5
references: 11852290
references: J Neuroimmunol. 2002 Feb;123(1-2):188-92
references: 11880163
references: Neurology. 2002 Apr 23;58(8 Suppl 4):S3-9
references: 11971121
references: Neurology. 2002 Sep 24;59(6):802-8
references: 12349849
references: Brain. 2002 Nov;125(Pt 11):2381-91
references: 12390966
references: Neurology. 2002 Oct 22;59(8):1284-6
references: 12391370
references: Ann Neurol. 2003 Mar;53(3):292-304
references: 12601697
references: Mult Scler. 2003 Feb;9(1):16-20
references: 12617262
references: Trends Pharmacol Sci. 2003 Mar;24(3):131-8
references: 12628358
references: Mult Scler. 2003 Aug;9(4):349-55
references: 12926839
references: Eur J Neurol. 2003 Nov;10(6):671-6
references: 14641512
references: Proc Natl Acad Sci U S A. 2003 Nov 25;100(24):14157-62
references: 14614135
references: Cochrane Database Syst Rev. 2004;(1):CD004678
references: 14974077
references: Expert Opin Pharmacother. 2004 Apr;5(4):875-91
references: 15102570
references: Neurology. 2004 Apr 27;62(8):1432-4
references: 15111692
references: Mult Scler. 2004 Jun;10 Suppl 1:S65-71; discussion S71-2
references: 15218813
references: Eur J Immunol. 1971 Aug;1(4):242-8
references: 5157960
references: J Neurol Sci. 1977 Apr;31(3):433-8
references: 845620
references: Ann Neurol. 1982 Mar;11(3):317-9
references: 7092185